Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.Key Opinion Leader investor webinar scheduled for October 6, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results